PDCD1 and melanoma: The number of TREM2+ TAMs is correlated with unfavorable survival or with a worse response rate to PD-1-based immune checkpoint inhibitors in patients with colorectal cancer, lung cancer, hepatocellular carcinoma, or melanoma [80–85].